Artrya Secured Huntsville Hospital Health System Deal

The medical technology firm signed a five-year contract to integrate its Salix platform into the local hospital network.

Updated on Oct. 2, 2026 in Healthcare

Isometric editorial illustration of a geometric model representing vascular pathways, evoking clinical software integration. — Artrya Limited has signed a five-year contract to integrate its Salix diagnostic platform across the 15-facility Huntsville Hospital Health System network. AI Illustration. Upload story photo >

Live Poll

Do you believe commercial partnerships between hospitals and tech companies improve local healthcare quality?

Artrya Limited has entered into a five-year commercial agreement with Huntsville Hospital Health System. This partnership makes the health system, which operates a 15-hospital network, the largest customer deployment for the medical technology company in the United States.

Why it matters

This agreement serves as a key pillar of Artrya's broader market strategy to expand its footprint in the United States. Integrating the Salix platform into existing clinical workflows aims to support the company's growth objectives across the American healthcare sector.

The deal guarantees a minimum contracted value of US$0.5 million over its five-year term. This partnership marks a significant expansion for Artrya, which currently reports four total commercial customers in the United States.

The players

Artrya Limited

Artrya Limited is a medical technology group focused on diagnostic solutions for coronary artery disease.

Huntsville Hospital Health System

Huntsville Hospital Health System is a regional network operating 15 hospitals that previously engaged with Artrya during the SAPPHIRE Study.

The details

The contract involves the integration of Artrya’s Salix platform into clinical workflows at the network's 15 facilities. Revenue from the agreement is generated through monthly software-as-a-service subscription fees for Salix Coronary Anatomy and a fee-per-scan model for Salix Coronary Plaque.

October 2, 2026: The five-year commercial deal was officially announced.
Five-year term: The duration of the commercial agreement between the two entities.

Market Landscape

This commercial partnership marks a progression from the preliminary clinical engagement previously conducted through the SAPPHIRE Study. It shifts the company from research-based collaboration to a formal deployment model within a large-scale hospital network.

The integration of this software platform into the local healthcare network may streamline diagnostic clinical workflows for patients within the system. Residents should see no direct changes to their personal billing or access to care as a result of this technology implementation.

The takeaway

This partnership demonstrates the transition of specialized diagnostic software from trial environments into routine clinical practice. Patients and providers can expect increased reliance on automated tools for assessing coronary anatomy as these platforms scale within large health systems.